Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2015

Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2015

Feb 2015 Global Markets Direct Lymphoma175 Pages Price :
$ 2000
Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2015

Summary

Global Markets Directs, Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2015, provides an overview of the Cutaneous T-Cell Lymphomas therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cutaneous T-Cell Lymphoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Cutaneous T-Cell Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Cutaneous T-Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cutaneous T-Cell Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cutaneous T-Cell Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cutaneous T-Cell Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
rsities/Institutes 14
Cutaneous T-Cell Lymphoma - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Cutaneous T-Cell Lymphoma - Products under Development by Companies 18
Cutaneous T-Cell Lymphoma - Products under Investigation by Universities/Institutes 20
Cutaneous T-Cell Lymphoma - Companies Involved in Therapeutics Development 21
Affimed Therapeutics AG 21
Chipscreen Biosciences Ltd 22
Cornerstone Pharmaceuticals, Inc. 23
Cyclacel Pharmaceuticals, Inc. 24
Eisai Co., Ltd. 25
Galderma S.A. 26
Innate Pharma SA 27
Johnson & Johnson 28
Karyopharm Therapeutics, Inc. 29
Kyowa Hakko Kirin Co., Ltd. 30
MedImmune, LLC 31
Neumedicines Inc. 32
Novartis AG 33
OncoSec Medical Inc. 34
Onyx Pharmaceuticals, Inc. 35
Sanofi 36
Soligenix, Inc. 37
Taiwan Liposome Company, Ltd. 38
Takeda Pharmaceutical Company Limited 39
TetraLogic Pharmaceuticals 40
Cutaneous T-Cell Lymphoma - Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Target 42
Assessment by Mechanism of Action 44
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
A-dmDT390-bisFv - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
AFM-13 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
alemtuzumab - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
AMP-224 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Angeloxin - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
bexarotene - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
brentuximab vedotin - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
carfilzomib - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
CIGB-128 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
CPI-613 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
CS-055 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
DNA IL-12 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
everolimus - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
IPH-4102 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
mogamulizumab - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
NMIL-121 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
quisinostat - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
sapacitabine - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
selinexor - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
SGX-301 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
SHP-141 - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
trifarotene - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
vinorelbine tartrate - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Cutaneous T-Cell Lymphoma - Recent Pipeline Updates 102
Cutaneous T-Cell Lymphoma - Dormant Projects 164
Cutaneous T-Cell Lymphoma - Discontinued Products 167
Cutaneous T-Cell Lymphoma - Product Development Milestones 168
Featured News & Press Releases 168
Jan 07, 2015: FDA Grants Soligenix Fast TrackDesignation for SGX301 for the First-Line Treatment of Cutaneous T-Cell Lymphoma 168
Dec 18, 2014: TetraLogic Announces Initiation of a Randomized Phase 2 Clinical Trial of SHAPE in Subjects With Cutaneous T-Cell Lymphoma 168
Nov 03, 2014: IPH 4102 Preclinical Data Published In Cancer Research 169
Sep 17, 2014: Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 169
Aug 27, 2014: Innate Pharma's IPH4102 Receives Orphan Drug Designation In European Union 170
Apr 08, 2014: Seattle Genetics Achieves Milestones Under Collaboration with Takeda for Achieving First Commercial Sales of ADCETRIS in Key Countries 170
Apr 07, 2014: OncoSec Medical To Relaunch Phase II Cutaneous T-Cell Lymphoma Study at Key Centers of Excellence 171
Mar 17, 2014: Approval for Additional Indication for PTCL and CTCL of Mogamulizumab 172
Jan 15, 2014: Addition of Japanese Sites for Pivotal Phase 3 Trial of Mogamulizumab in Patients with Cutaneous T-Cell Lymphoma 173
Oct 08, 2013: OncoSec Medical Announces Positive Preliminary Safety Data in Combination Study 173
Appendix 174
Methodology 174
Coverage 174
Secondary Research 174
Primary Research 174
Expert Panel Validation 174
Contact Us 174
Disclaimer 175

List of Tables
Number of Products under Development for Cutaneous T-Cell Lymphoma, H1 2015 10
Number of Products under Development for Cutaneous T-Cell Lymphoma - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 12
Number of Products under Development by Companies, H1 2015 (Contd..1) 13
Number of Products under Investigation by Universities/Institutes, H1 2015 14
Comparative Analysis by Late Stage Development, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Products under Development by Companies, H1 2015 18
Products under Development by Companies, H1 2015 (Contd..1) 19
Products under Investigation by Universities/Institutes, H1 2015 20
Cutaneous T-Cell Lymphoma - Pipeline by Affimed Therapeutics AG, H1 2015 21
Cutaneous T-Cell Lymphoma - Pipeline by Chipscreen Biosciences Ltd, H1 2015 22
Cutaneous T-Cell Lymphoma - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2015 23
Cutaneous T-Cell Lymphoma - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2015 24
Cutaneous T-Cell Lymphoma - Pipeline by Eisai Co., Ltd., H1 2015 25
Cutaneous T-Cell Lymphoma - Pipeline by Galderma S.A., H1 2015 26
Cutaneous T-Cell Lymphoma - Pipeline by Innate Pharma SA, H1 2015 27
Cutaneous T-Cell Lymphoma - Pipeline by Johnson & Johnson, H1 2015 28
Cutaneous T-Cell Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 29
Cutaneous T-Cell Lymphoma - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 30
Cutaneous T-Cell Lymphoma - Pipeline by MedImmune, LLC, H1 2015 31
Cutaneous T-Cell Lymphoma - Pipeline by Neumedicines Inc., H1 2015 32
Cutaneous T-Cell Lymphoma - Pipeline by Novartis AG, H1 2015 33
Cutaneous T-Cell Lymphoma - Pipeline by OncoSec Medical Inc., H1 2015 34
Cutaneous T-Cell Lymphoma - Pipeline by Onyx Pharmaceuticals, Inc., H1 2015 35
Cutaneous T-Cell Lymphoma - Pipeline by Sanofi, H1 2015 36
Cutaneous T-Cell Lymphoma - Pipeline by Soligenix, Inc., H1 2015 37
Cutaneous T-Cell Lymphoma - Pipeline by Taiwan Liposome Company, Ltd., H1 2015 38
Cutaneous T-Cell Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 39
Cutaneous T-Cell Lymphoma - Pipeline by TetraLogic Pharmaceuticals, H1 2015 40
Assessment by Monotherapy Products, H1 2015 41
Number of Products by Stage and Target, H1 2015 43
Number of Products by Stage and Mechanism of Action, H1 2015 45
Number of Products by Stage and Route of Administration, H1 2015 47
Number of Products by Stage and Molecule Type, H1 2015 49
Cutaneous T-Cell Lymphoma Therapeutics - Recent Pipeline Updates, H1 2015 102
Cutaneous T-Cell Lymphoma - Dormant Projects, H1 2015 164
Cutaneous T-Cell Lymphoma - Dormant Projects (Contd..1), H1 2015 165
Cutaneous T-Cell Lymphoma - Dormant Projects (Contd..2), H1 2015 166
Cutaneous T-Cell Lymphoma - Discontinued Products, H1 2015 167

List of Tables
Number of Products under Development for Cutaneous T-Cell Lymphoma, H1 2015 10
Number of Products under Development for Cutaneous T-Cell Lymphoma - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 12
Number of Products under Development by Companies, H1 2015 (Contd..1) 13
Number of Products under Investigation by Universities/Institutes, H1 2015 14
Comparative Analysis by Late Stage Development, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Products under Development by Companies, H1 2015 18
Products under Development by Companies, H1 2015 (Contd..1) 19
Products under Investigation by Universities/Institutes, H1 2015 20
Cutaneous T-Cell Lymphoma - Pipeline by Affimed Therapeutics AG, H1 2015 21
Cutaneous T-Cell Lymphoma - Pipeline by Chipscreen Biosciences Ltd, H1 2015 22
Cutaneous T-Cell Lymphoma - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2015 23
Cutaneous T-Cell Lymphoma - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2015 24
Cutaneous T-Cell Lymphoma - Pipeline by Eisai Co., Ltd., H1 2015 25
Cutaneous T-Cell Lymphoma - Pipeline by Galderma S.A., H1 2015 26
Cutaneous T-Cell Lymphoma - Pipeline by Innate Pharma SA, H1 2015 27
Cutaneous T-Cell Lymphoma - Pipeline by Johnson & Johnson, H1 2015 28
Cutaneous T-Cell Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 29
Cutaneous T-Cell Lymphoma - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 30
Cutaneous T-Cell Lymphoma - Pipeline by MedImmune, LLC, H1 2015 31
Cutaneous T-Cell Lymphoma - Pipeline by Neumedicines Inc., H1 2015 32
Cutaneous T-Cell Lymphoma - Pipeline by Novartis AG, H1 2015 33
Cutaneous T-Cell Lymphoma - Pipeline by OncoSec Medical Inc., H1 2015 34
Cutaneous T-Cell Lymphoma - Pipeline by Onyx Pharmaceuticals, Inc., H1 2015 35
Cutaneous T-Cell Lymphoma - Pipeline by Sanofi, H1 2015 36
Cutaneous T-Cell Lymphoma - Pipeline by Soligenix, Inc., H1 2015 37
Cutaneous T-Cell Lymphoma - Pipeline by Taiwan Liposome Company, Ltd., H1 2015 38
Cutaneous T-Cell Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 39
Cutaneous T-Cell Lymphoma - Pipeline by TetraLogic Pharmaceuticals, H1 2015 40
Assessment by Monotherapy Products, H1 2015 41
Number of Products by Stage and Target, H1 2015 43
Number of Products by Stage and Mechanism of Action, H1 2015 45
Number of Products by Stage and Route of Administration, H1 2015 47
Number of Products by Stage and Molecule Type, H1 2015 49
Cutaneous T-Cell Lymphoma Therapeutics - Recent Pipeline Updates, H1 2015 102
Cutaneous T-Cell Lymphoma - Dormant Projects, H1 2015 164
Cutaneous T-Cell Lymphoma - Dormant Projects (Contd..1), H1 2015 165
Cutaneous T-Cell Lymphoma - Dormant Projects (Contd..2), H1 2015 166
Cutaneous T-Cell Lymphoma - Discontinued Products, H1 2015 167

List of Figures
Number of Products under Development for Cutaneous T-Cell Lymphoma, H1 2015 10
Number of Products under Development for Cutaneous T-Cell Lymphoma - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 16
Assessment by Monotherapy Products, H1 2015 41
Number of Products by Top 10 Targets, H1 2015 42
Number of Products by Stage and Top 10 Targets, H1 2015 42
Number of Products by Top 10 Mechanism of Actions, H1 2015 44
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 44
Number of Products by Top 10 Routes of Administration, H1 2015 46
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 47
Number of Products by Top 10 Molecule Types, H1 2015 48
Number of Products by Stage and Top 10 Molecule Types, H1 2015 49

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Country :
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 2000
$ 4000

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top